ConforMIS, Inc. (NASDAQ:CFMS) CTO Daniel Steines sold 15,485 shares of ConforMIS stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $3.15, for a total value of $48,777.75. Following the completion of the transaction, the chief technology officer now owns 254,652 shares of the company’s stock, valued at approximately $802,153.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Daniel Steines also recently made the following trade(s):

  • On Wednesday, October 18th, Daniel Steines sold 907 shares of ConforMIS stock. The shares were sold at an average price of $3.51, for a total value of $3,183.57.

ConforMIS, Inc. (NASDAQ:CFMS) traded up $0.06 during mid-day trading on Friday, reaching $3.27. The company had a trading volume of 387,530 shares, compared to its average volume of 299,113. The company has a debt-to-equity ratio of 0.52, a quick ratio of 5.38 and a current ratio of 6.19. ConforMIS, Inc. has a 12 month low of $3.03 and a 12 month high of $9.59.

ConforMIS (NASDAQ:CFMS) last posted its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.03. ConforMIS had a negative return on equity of 76.88% and a negative net margin of 72.70%. The company had revenue of $18.40 million for the quarter, compared to analysts’ expectations of $17.55 million. During the same period in the previous year, the firm posted ($0.31) EPS. ConforMIS’s revenue was down 1.3% compared to the same quarter last year. analysts expect that ConforMIS, Inc. will post -1.28 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “ConforMIS, Inc. (CFMS) CTO Daniel Steines Sells 15,485 Shares” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/18/conformis-inc-cfms-cto-daniel-steines-sells-15485-shares.html.

Several equities analysts recently weighed in on the company. Deutsche Bank AG restated a “hold” rating and issued a $5.00 price target (down previously from $6.00) on shares of ConforMIS in a research note on Friday, August 4th. Oppenheimer Holdings, Inc. set a $6.00 price target on ConforMIS and gave the company a “buy” rating in a research note on Friday, August 4th. ValuEngine upgraded ConforMIS from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. BTIG Research restated a “hold” rating on shares of ConforMIS in a research note on Thursday, November 2nd. Finally, Zacks Investment Research cut ConforMIS from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $5.85.

A number of hedge funds have recently bought and sold shares of CFMS. Granite Investment Partners LLC acquired a new stake in ConforMIS in the 3rd quarter worth about $859,000. Goldman Sachs Group Inc. boosted its holdings in ConforMIS by 1,313.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 148,147 shares of the medical instruments supplier’s stock worth $773,000 after buying an additional 137,667 shares during the last quarter. Ark Investment Management LLC boosted its holdings in ConforMIS by 208.5% in the 2nd quarter. Ark Investment Management LLC now owns 192,378 shares of the medical instruments supplier’s stock worth $825,000 after buying an additional 130,009 shares during the last quarter. Spark Investment Management LLC acquired a new position in shares of ConforMIS during the 2nd quarter worth approximately $430,000. Finally, Citadel Advisors LLC boosted its holdings in shares of ConforMIS by 331.2% during the 3rd quarter. Citadel Advisors LLC now owns 113,972 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 87,540 shares during the last quarter. Institutional investors own 32.83% of the company’s stock.

ConforMIS Company Profile

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Insider Buying and Selling by Quarter for ConforMIS (NASDAQ:CFMS)

Receive News & Stock Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related stocks with our FREE daily email newsletter.